Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Preferred Stock Liabilities: 2020

Historic Preferred Stock Liabilities for Candel Therapeutics (CADL) over the last 1 years, with Dec 2020 value amounting to $26.6 million.

  • Candel Therapeutics' Preferred Stock Liabilities was N/A to $26.6 million in Q2 2021 from the same period last year, while for Jun 2021 it was $26.6 million, marking a year-over-year change of. This contributed to the annual value of $26.6 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Candel Therapeutics reported Preferred Stock Liabilities of $26.6 million as of FY2020.
  • Candel Therapeutics' Preferred Stock Liabilities' 5-year high stood at $26.6 million during FY2020, with a 5-year trough of $26.6 million in FY2020.
  • Moreover, its 1-year median value for Preferred Stock Liabilities was $26.6 million (2020), whereas its average is $26.6 million.